A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Medical Director
Merck Sharp & Dohme LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
285 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Blacktown Hospital ( Site 0002)
Blacktown, New South Wales, Australia
- Macquarie University-Mq Health Clinical Trials Unit ( Site 0003)
Macquarie University, New South Wales, Australia
- Tamworth Hospital-North West Cancer Centre ( Site 0006)
North Tamworth, New South Wales, Australia
- Royal Brisbane and Women'S Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 0001)
Brisbane, Queensland, Australia
- Lyell Mcewin Hospital-Oncology Clinical Trials Unit ( Site 0008)
Elizabeth Vale, South Australia, Australia
- Austin Health-Cancer Clinical Trials Centre ( Site 0005)
Heidelberg, Victoria, Australia
- Fiona Stanley Hospital-Medical Oncology ( Site 0004)
Murdoch, Western Australia, Australia
- Hospital São Carlos-Oncocentro Ce ( Site 0104)
Fortaleza, Ceará, Brazil
- Centro Avançado de Tratamento Oncológico- Cenantron-Clinical Research ( Site 0105)
Belo Horizonte, Minas Gerais, Brazil
- Instituto Do Câncer E Transplante de Curitiba ( Site 0102)
Curitiba, Paraná, Brazil
- Liga Norte Riograndense Contra O Câncer-Centro de Pesquisa Clínica ( Site 0103)
Natal, Rio Grande do Norte, Brazil
- Hospital Nossa Senhora Da Conceição-Centro Integrado de Pesquisa Em Oncologia ( Site 0101)
Porto Alegre, Rio Grande do Sul, Brazil
- Hospital de Clínicas de Ribeirão Preto ( Site 0112)
Ribeirão Preto, São Paulo, Brazil
- Bp - A Beneficencia Portuguesa de São Paulo ( Site 0111)
São Paulo, Brazil
- Mbal Uni Hospital-Department of Medical Oncology ( Site 0204)
Panagyurishte, Pazardzhik, Bulgaria
- Mhat Serdika-Second Department of Medical Oncology ( Site 0203)
Sofia, Sofia (stolitsa), Bulgaria
- Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0205)
Plovdiv, Bulgaria
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 3706)
Calgary, Alberta, Canada
- Bc Cancer Vancouver-Clinical Trials Unit ( Site 3707)
Vancouver, British Columbia, Canada
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 3710)
Hamilton, Ontario, Canada
- London Health Sciences Centre ( Site 3705)
London, Ontario, Canada
- Princess Margaret Cancer Centre ( Site 3703)
Toronto, Ontario, Canada
- Ciusss de L'Est-de-L'Île-de-Montréal ( Site 3708)
Montreal, Quebec, Canada
- Mcgill University Health Centre ( Site 3709)
Montreal, Quebec, Canada
- Centre Intégré de Cancérologie Du Chu de Québec Université Laval, Hôpital de L'Enfant-Jésus ( Site 3701)
Québec, Quebec, Canada
- James Lind Centro de Investigacion del Cancer ( Site 0307)
Temuco, Araucania, Chile
- Clínica Puerto Montt ( Site 0309)
Port Montt, Los Lagos Region, Chile
- Oncocentro Valdivia ( Site 0312)
Valdivia, Los Ríos Region, Chile
- Bradfordhill ( Site 0305)
Santiago, Region M. de Santiago, Chile
- Falp-Uido ( Site 0302)
Santiago, Region M. de Santiago, Chile
- Oncovida ( Site 0306)
Santiago, Region M. de Santiago, Chile
- Oncocentro Apys-Acerey ( Site 0301)
Viña del Mar, Valparaiso, Chile
- Bradford Hill Norte ( Site 0303)
Antofagasta, Chile
- the First Affiliated Hospital of Bengbu Medical University- Urology Surgery ( Site 0438)
Bengbu, Anhui, China
- the Second Hospital of Anhui Medical University ( Site 0416)
Hefei, Anhui, China
- Beijing Cancer Hospital-Urinary Surgery ( Site 0406)
Beijing, Beijing Municipality, China
- Cancer Hospital Chinese Academy of Medical Sciences ( Site 0435)
Beijing, Beijing Municipality, China
- First Medical Center of Chinese Pla General Hospital ( Site 0415)
Beijing, Beijing Municipality, China
- Peking University First Hospital-Urology ( Site 0407)
Beijing, Beijing Municipality, China
- Army Medical Center of People'S Liberation Army ( Site 0439)
Chongqing, Chongqing Municipality, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Mar 2022
- Primary completion
- 28 Oct 2026
- Completion
- 28 Sept 2029
- Last update posted
- 15 May 2026
- Registered enrollment
- 1,800
- Registry id
- NCT05239728
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.